Follow-up for people treated with gene-modified T cells
Part of Cancer clinical trials.
This study is a long-term check-in for people who previously received gene-modified T-cell infusions in a related Celgene/Juno/BMS trial. It helps researchers track safety and long-term effects over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have received at least one gene-modified T-cell infusion in a previous related Celgene/Juno/BMS-affiliated trial.
- You must have finished the post-treatment follow-up in that earlier (parent) study, or stopped participation when that follow-up ended.
- You must understand the study and be willing to sign the informed consent form (or assent form, if applicable).
- You must agree to complete any study-related checks or procedures they ask for.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how people do over time after receiving an “adoptive cell therapy” treatment. It helps researchers understand long-term safety and outcomes after prior participation in related studies.
This study is a long-term follow-up for people who already received gene therapy for sickle cell disease in a specific sponsor’s clinical trial. It helps researchers watch for long-term safety and outcomes over time.
This study checks long-term health after receiving a gene-modified cell therapy through a St. Jude study. It helps doctors understand the treatment’s lasting effects and safety over time.
This study is a long-term safety check for people who have already received a gene modified T cell treatment in a previous study sponsored by 2seventy bio or Regeneron Pharmaceuticals. The goal is to monitor your health for years after that treatment to see how well it works and if any side effects appear over time.
This study checks your health over time after you previously received gene-modified cell therapy in a Sorrento-sponsored trial. It helps researchers understand long-term safety and outcomes and may lead to better care for future patients.
This is a long-term follow-up study for people who have already received gene-modified T-cell therapy. It observes your health over time to see how well the treatment worked and any long-term effects.
Hear when a new Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.